세계의 신경영양성 각막염 치료 시장 규모 : 치료별, 지역별, 범위 및 예측

Neurotrophic Keratitis Treatment Market Size And Forecast

Neurotrophic Keratitis Treatment Market size was valued at USD 4.4 Billion in 2023 and is projected to reach USD 8.81 Billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030.

Global Neurotrophic Keratitis Treatment Market Drivers

The market drivers for the Neurotrophic Keratitis Treatment Market can be influenced by various factors. These may include: Rising Neurotrophic Keratitis Prevalence: One important factor is the increasing prevalence of neurotrophic keratitis, which is frequently linked to diseases including diabetes, herpes zoster, and difficulties following surgery. Because older people are more susceptible to these underlying illnesses, an ageing population also plays a role in the rising prevalence.

Progress in Diagnostic Methods:

The need for treatment options is increasing due to advancements in diagnostic techniques that enable early and accurate identification of neurotrophic keratitis. Improved biomarker discovery and imaging technologies are contributing to improved disease management.

Creation of Innovative Treatments:

The market is growing due to the development of novel therapeutic drugs and cutting-edge treatments such recombinant human nerve growth factor (cenegermin). Better patient outcomes are possible thanks to these innovative treatments, which offer more focused and efficient methods.

Enhanced Knowledge and Sensitization:

The market is expanding as a result of patients' and healthcare professionals' increasing knowledge of neurotrophic keratitis and available treatments. More awareness and comprehension of the illness are being fostered by educational initiatives and an increase in research publications.

Expenditure on Scientific and Technological Research:

The identification of new treatment modalities is being facilitated by large investments made in research and development by pharmaceutical corporations and academic institutions. This is creating a strong pipeline of possible treatments and driving market expansion.

Regulatory Acceptance and Assistance:

Market expansion is being aided by favourable regulatory environments and the FDA and EMA approving novel therapies. Accelerated review procedures and regulatory assistance for orphan drug status are also advantageous.

Innovations in Technology:

Technological developments in medication delivery, like sustained-release formulations and nanotechnology-based methods, are improving the convenience and effectiveness of treatments for neurotrophic keratitis, which is propelling the market's expansion.

Increasing Costs of Healthcare:

Government and business sector funding on healthcare is improving access to cutting-edge neurotrophic keratitis treatments. Further fostering market expansion are better reimbursement guidelines and healthcare infrastructure.

Expanding Use of Procedures With Minimal Invasiveness:

The market is being positively impacted by the desire for less intrusive treatment choices that have shorter recovery times and a lower risk of consequences. The use of these techniques to treat neurotrophic keratitis is growing in acceptance.

Partnerships & Cooperations: Innovation in neurotrophic keratitis treatments is being propelled by strategic alliances and partnerships among research organisations, pharmaceutical businesses, and healthcare providers. The goal of these partnerships is frequently to hasten the creation and marketing of novel treatments.

Global Neurotrophic Keratitis Treatment Market Restraints

Several factors can act as restraints or challenges for the Neurotrophic Keratitis Treatment Market. These may include:

Exorbitant Treatment Costs:

Surgical procedures and cutting-edge therapy options, such as recombinant human nerve growth factor (rhNGF), can be highly costly for treating neurotrophic keratitis. Patients may find this to be less accessible, particularly in areas without universal healthcare.

Insufficient Knowledge and Diagnosis:

Since neurotrophic keratitis is an uncommon condition, both patients and medical professionals frequently lack knowledge about it. This may result in an incorrect or underdiagnosis, which would decrease the number of patients receiving the right care.

Regulatory Difficulties:

Getting novel treatments approved by the authorities can be an expensive and time-consuming procedure. New treatments may take longer to reach the market due to the strict regulations imposed by organisations like the FDA and EMA.

Availability of Alternative therapies:

The demand for more expensive, more advanced therapies may decline if there are more affordable alternatives available, such as traditional eye drops, ointments, and autologous serum eye drops. These less expensive options may be preferred by certain healthcare professionals and patients.

Safety concerns and adverse effects:

Patients may be discouraged from taking certain NK therapies because to their unpleasant side effects. Adoption of novel therapies may be hindered by safety concerns until long-term safety and efficacy evidence become available.

Insurance and Reimbursement Issues:

There might be variability in insurance coverage for NK treatments, with certain treatments not receiving any coverage at all. Patients may incur significant out-of-pocket costs as a result, further restricting their access to efficacious treatments.

Limited Research and Development:

Compared to more prevalent illnesses, there is comparatively less research and development activity because of the disease's rarity. This may impede the development of novel therapies and the advancement of current ones.

Economic Restrictions:

In low- and middle-income nations, financial restrictions may severely restrict access to cutting-edge NK treatments. The broad availability and usage of sophisticated medicines may be hindered by the inadequate healthcare infrastructure in these locations.

Patient Compliance:

Strict adherence to pharmaceutical regimens is often necessary for NK treatments, which might provide difficulties for patients. Non-compliance may result in less than ideal treatment results, which lowers the therapies' perceived efficacy.

Lack of Specialist Care:

Ophthalmologists with experience treating corneal illnesses are typically needed to treat neurotrophic keratitis. The lack of these specialists can be a major obstacle to providing quality care, particularly in poor and rural locations

Global Neurotrophic Keratitis Treatment Market Segmentation Analysis

The Global Neurotrophic Keratitis Treatment Market is segmented on the basis of Treatment and Geography.

Neurotrophic Keratitis Treatment Market, By Treatment

• Topical Antibiotics
• Recombinant Human Nerve Growth Factor (rhNGF)
• Amniotic Membrane Transplantation
• Keratoplasty
• Others

Based on Treatment, the market is bifurcated into Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, and Others. The dominance of topical antibiotics in the Neurotrophic Keratitis Treatment Market in the past few years can be attributed to several factors. Topical antibiotics are effective in managing neurotrophic keratitis because they have antimicrobial properties. Neurotrophic keratitis can make the cornea vulnerable to infections, and topical antibiotics help prevent or treat these infections, reducing the risk of complications.

• Topical antibiotics have been a conventional and widely used treatment approach for various corneal conditions, including neurotrophic keratitis. Healthcare professionals are familiar with their use, and readily available in numerous formulations, making them a preferred choice for initial treatment. Topical antibiotics often have a broad spectrum of action, targeting many bacteria that may cause corneal infections. This versatility makes them suitable for treating different bacterial infections associated with neurotrophic keratitis. Topical antibiotics are typically administered as eye drops or ointments, making them easy to apply.
• Patients can often self-administer these medications at home, which improves treatment compliance and convenience. The neurotrophic keratitis treatment landscape is constantly evolving. Emerging treatment options, such as recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, and keratoplasty, are gaining attention and showing promising results in clinical studies. While topical antibiotics have been dominant in the past, the market dynamics may shift as newer treatment modalities gain acceptance and demonstrate their efficacy in managing neurotrophic keratitis. Therefore, monitoring the latest developments and research findings is essential to stay updated on the evolving treatment landscape.

Neurotrophic Keratitis Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the Global Neurotrophic Keratitis Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Neurotrophic Keratitis Treatment Market has been identified as having high growth potential in the Asia Pacific area. The Asia Pacific region has the largest population, including a growing elderly population. Neurotrophic keratitis is more prevalent among the elderly, and as the population ages over time, the demand for neurotrophic keratitis treatment is expected to increase.
• Many major countries in the Asia Pacific region are experiencing rapid economic growth and increasing healthcare expenditure. This provides greater accessibility to healthcare services, including neurotrophic keratitis treatment, and drives market growth. Several other countries in the Asia Pacific region have been investing in improving their healthcare infrastructure. This includes the development of specialized eye care centers, advanced medical facilities, and increased availability of treatment options, which contribute to the growth of the Neurotrophic Keratitis Treatment Market.

Key Players

• The major players in the Neurotrophic Keratitis Treatment Market are
• Santen Pharmaceutical Co. Ltd.
• Novartis AG
• RegeneRx
• Biopharmaceuticals Inc.
• Dompe farmaceutici S.p.A.
• Dompe Farma S.r.l.
• Horizon Therapeutics plc
• AuroLab
• Genentech Inc. (a subsidiary of Roche Holding AG)
• Johnson & Johnson Services Inc.
• Allergan (a subsidiary of AbbVie Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET, BY TREATMENT

• 5.1 Topical Antibiotics
• 5.2Recombinant Human Nerve Growth Factor (rhNGF)
• 5.3Amniotic Membrane Transplantation
• 5.4Keratoplasty
• 5.5Others

6 GLOBAL EUROTROPHIC KERATITIS TREATMENT MARKET, BY GEOGRAPHY

• 6.1 Overview
• 6.2 North America
  • 6.2.1 U.S.
  • 6.2.2 Canada
  • 6.2.3 Mexico
• 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 U.K.
  • 6.3.3 France
  • 6.3.4 Rest of Europe
• 6.4 Asia Pacific
  • 6.4.1 China
  • 6.4.2 Japan
  • 6.4.3 India
  • 6.4.4 Rest of Asia Pacific
• 6.5 Rest of the World
  • 6.5.1 Latin America
  • 6.5.2 Middle East & Africa

7 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 7.1 Overview
• 7.2 Company Market Ranking
• 7.3 Key Development Strategies

8 COMPANY PROFILES

• 8.1 Santen Pharmaceutical Co. Ltd.
• 8.1 Novartis AG
• 8.2 RegeneRx
• 8.3 Biopharmaceuticals Inc.
• 8.4 Dompe farmaceutici S.p.A.
• 8.5 Dompe Farma S.r.l.
• 8.6 Horizon Therapeutics plc
• 8.7 AuroLab
• 8.8 Genentech Inc. (a subsidiary of Roche Holding AG)
• 8.9 Johnson & Johnson Services Inc.
• 8.10 Allergan (a subsidiary of AbbVie Inc.

9 Appendix

• 9.1 Related Research